Airsculpt Technologies Inc (AIRS)vsEli Lilly and Company (LLY)
AIRS
Airsculpt Technologies Inc
$5.11
-10.51%
HEALTHCARE · Cap: $382.36M
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 47484% more annual revenue ($72.25B vs $151.84M). LLY leads profitability with a 35.0% profit margin vs -7.4%. LLY earns a higher WallStSmart Score of 78/100 (B+).
AIRS
Avoid34
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.7%
Fair Value
$2.40
Current Price
$5.11
$2.71 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 200.0% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
0.0% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -11.2% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AIRS
The strongest argument for AIRS centers on EPS Growth.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : AIRS
The primary concerns for AIRS are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
AIRS profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.02 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 34/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is a pioneering company in the aesthetic medical technology sector, renowned for its innovative AirSculpt® procedure that delivers minimally invasive body contouring with a strong commitment to patient safety and comfort. The company is strategically expanding its network of licensed practitioners, supported by a robust focus on technological advancements, which positions Airsculpt favorably within the rapidly growing non-invasive cosmetic treatment market. As consumer demand for aesthetic solutions continues to rise globally, Airsculpt is well-positioned to enhance its market share and diversify its service offerings, aiming to achieve substantial growth and sustainable value for its investors.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?